Keywords: Novavax, H1N1 flu vaccine, Research

Novavax leaps on positive results from pivotal study of 2009 A/H1N1 VLP flu vaccine

Article | 25 March 2010

Print This

US vaccine developer Novavax saw its share price leap13% to $2.65 after it announced positive results from a pivotal study of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in